SleepCited

A case series on the use of lavendula oil capsules in patients suffering from major depressive disorder and symptoms of psychomotor agitation, insomnia and anxiety.

Maria Fißler, Arnim Quante
Case Report Complementary therapies in medicine 2014 40 件の引用

研究デザイン

研究タイプ
Case Reports
サンプルサイズ
8
対象集団
Patients with major depressive disorder (MDD) and symptoms of anxiety, insomnia, and psychomotor agitation at Charité-Universitätsmedizin Berlin
介入
A case series on the use of lavendula oil capsules in patients suffering from major depressive disorder and symptoms of psychomotor agitation, insomnia and anxiety. Lasea (lavender oil capsules) 80 mg; dosage details not specified
比較対照
antidepressant medications (adjunct use)
主要アウトカム
Change in Hamilton Rating Scale for Depression (HAMD-17) total score and subscores
効果の方向
Positive
バイアスリスク
High

抄録

OBJECTIVE: Symptoms of agitation, anxiety and insomnia are frequent among patients with major depressive disorder (MDD) during the first weeks of psychiatric care. But a substantial number of patients declines taking pharmaceutical medication to avoid side effects. Therefore, an alternative herbal medication is needed. Clinical studies demonstrated that lavender oil capsules, termed Lasea®, have an anxiolytic effect comparable to Lorazepam and significantly reduce insomnia and agitation in non-depressed patients. Therefore, the aim of this retrospective case series was to analyze the effectiveness of Lasea® for patients with MDD and symptoms of anxiety, insomnia and psychomotor agitation. DESIGN: Eight cases were analyzed retrospectively regarding the dosage, length of treatment, possible side effects and effectiveness of Lasea®. SETTING: All cases were treated at the Department of Psychiatry at Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin in a naturalistic setting. MAIN OUTCOME MEASURE: Effectiveness was measured by a change in the Hamilton Rating Scale for Depression (HAMD-17) total score and subscores. RESULTS: In 6 cases, the combination of Lasea® and an antidepressant resulted in a reduction of MDD. Lasea® also reduced agitation in 6 cases. Psychological anxiety was reduced in 5, somatic anxiety in 4 cases whereas sleep-onset and sleep-maintenance insomnia improved in 3 cases each. CONCLUSIONS: The results demonstrate that Lasea® reduces some of the anxiety related symptoms and sleep disturbances in MDD patients. Furthermore Lasea® significantly reduces psychomotor agitation. Additionally, the results indicate a significant global improvement stemming from the combinational therapy of Lasea® and antidepressant medication.

要約

The results demonstrate that Lasea® reduces some of the anxiety related symptoms and sleep disturbances in MDD patients and indicates a significant global improvement stemming from the combinational therapy of LaseA® and antidepressant medication.

エビデンスレビューでの引用